Myeloma Today: Spring 2020
Dear Reader
- A message from IMF President Susie Novis
Scientific & Clinical
- Immunotherapy in Myeloma: Attacking the Plasma Cell in New Ways
- The FDA Approves Isatuximab-irfc (Sarclisa®) for Relapsed Refractory Myeloma
Special Event
- Myeloma Action Month
Advocacy
- Diversity within clinical trials
Myeloma Warriors
- Magical Miles for Myeloma
click on the rectangle icon to view the publication fullscreen
with support from:
Amgen, Bristol-Myers Squibb, Genentech, and Takeda Oncology